Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party.
Between May 1988 and March 1995, 359 children with acute myeloid leukaemia (AML) were treated in the MRC AML 10 trial. Three risk groups were identified based on cytogenetics and response to treatment. One hundred and twenty-five children relapsed--103 in the bone marrow only, 12 in the bone marrow...
Main Authors: | Webb, D, Wheatley, K, Harrison, G, Stevens, R, Hann, I |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1999
|
Similar Items
-
Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.
by: Chessells, J, et al.
Published: (2002) -
Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
by: Harrison, G, et al.
Published: (2000) -
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.
by: Burnett, A, et al.
Published: (2002) -
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
by: Grimwade, D, et al.
Published: (1998) -
Treatment of high risk leukaemia - Results of MRC childhood acute lymphoblastic leukaemia study MRC HR-1.
by: Kinsey, S, et al.
Published: (2002)